Physician profile
Michael C Adams
NPI 1851383301
$5,507.07
in general payments reported to CMS, 2019-2025
33 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $366 · 2021: $326 · 2022: $570 · 2023: $874 · 2024: $1,106 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,888.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $996.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $518.06 | 2019-2025 | |
| Abbvie INC. | $253.23 | 2023-2025 | Ubrelvy, Vraylar |
| Abbott Laboratories | $200.86 | 2019-2025 | Eterna |
| Exact Sciences Corporation | $194.93 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $188.59 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $149.39 | 2022-2025 | |
| Lilly USA, LLC | $124.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Mallinckrodt Hospital Products INC. | $96.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $85.66 | 2024 | Austedo Xr |
| Amgen INC. | $82.88 | 2023-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.30 | 2022-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $56.20 | 2022-2023 | Livalo, Seglentis |
| Regeneron Healthcare Solutions, INC. | $51.62 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2019-2025 | Eliquis |
| Glaxosmithkline, LLC. | $48.06 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Bausch Health US, LLC | $46.82 | 2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $45.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.44 | 2021-2023 | |
| Lundbeck LLC | $31.96 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $31.21 | 2019-2025 | Capvaxive, Vaxneuvance |
| Neurocrine Biosciences, INC. | $29.86 | 2024 | Ingrezza |
| Viiv Healthcare Company | $29.82 | 2024-2025 | Apretude |
| Axsome Therapeutics, INC. | $29.23 | 2025 | Symbravo |
| Insulet Corporation | $28.42 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.73 | 2019 | |
| Sumitomo Pharma America, INC. | $25.21 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $23.83 | 2025 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $21.60 | 2024 | Aptima, Thinprep 2000 Processor, Third Wave |
| Medtronic, INC. | $14.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.